NeurAxis (NRXS) versus Its Competitors Financial Comparison

NeurAxis (NASDAQ:NRXS – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare NeurAxis to related companies based on the strength of its institutional ownership, dividends, profitability, valuation, analyst recommendations, earnings and risk.

Profitability

This table compares NeurAxis and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NeurAxis -492.76% N/A -641.25%
NeurAxis Competitors -300.62% -179.55% -22.71%

Insider and Institutional Ownership

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

NeurAxis has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, NeurAxis’ peers have a beta of 5.41, suggesting that their average stock price is 441% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for NeurAxis and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeurAxis 0 1 1 0 2.50
NeurAxis Competitors 4309 10596 18377 837 2.46

NeurAxis presently has a consensus price target of $13.00, indicating a potential upside of 139.85%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.26%. Given NeurAxis’ stronger consensus rating and higher possible upside, equities research analysts clearly believe NeurAxis is more favorable than its peers.

Valuation and Earnings

This table compares NeurAxis and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
NeurAxis $6.53 million -$14.63 million -5.11
NeurAxis Competitors $1.89 billion $136.85 million 6.01

NeurAxis’ peers have higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

NeurAxis peers beat NeurAxis on 9 of the 13 factors compared.

About NeurAxis

(Get Free Report)

NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and functional pain conditions. Its approach uses percutaneous electrical nerve field stimulation (PENFS), which delivers mild electrical impulses through nerves associated with the brain-gut pathway. The company’s lead product, IB-Stim, is a wearable, minimally invasive device cleared by the U.S. Food and Drug Administration for use as an adjunctive treatment for functional abdominal pain associated with irritable bowel syndrome in patients ages 11 to 18 who have not responded to conventional therapy.

Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.